Valuation Akeso, Inc.

Equities

Market Closed - Hong Kong S.E. Other stock markets 01:38:04 06/02/2026 pm IST			5-day change	1st Jan Change
100.90 ^HKD	-0.39%		-8.61%	-10.71%

06/02	Akeso, Inc. Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer	CI
03/02	Akeso granted exclusive commercialization rights for ebronucimab injection to Jumpcan Pharmaceutical	RE

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Capitalization ¹	25,184	22,632	31,991	35,423	51,197	82,534	82,534	-
Change	-	-10.13%	41.35%	10.73%	44.53%	61.21%	0%	-
Enterprise Value (EV) ¹	22,692	20,839	31,765	36,849	52,223	79,232	77,750	75,210
Change	-	-8.16%	52.43%	16%	41.72%	51.72%	-1.87%	-3.27%
P/E ratio	-19.4x	-21x	-26.8x	17.4x	-95.1x	-306x	110x	41.9x
PBR	6.32x	7.16x	11.9x	7.52x	7.12x	10.5x	9.29x	7.39x
PEG	-	1.1x	-3.54x	-0x	1x	6x	-0x	0x
Capitalization / Revenue	-	100x	38.2x	7.83x	24.1x	25.1x	15.7x	10.4x
EV / Revenue	-	92.4x	37.9x	8.14x	24.6x	24x	14.8x	9.46x
EV / EBITDA	-17.6x	-16x	-25.9x	16.8x	-143x	1,012x	63x	27x
EV / EBIT	-17.3x	-15.4x	-23.9x	18x	-93.6x	-307x	95.6x	32.3x
EV / FCF	-19.3x	-12.1x	-15.5x	23.2x	-46.6x	-182x	-10,724x	64x
FCF Yield	-5.17%	-8.24%	-6.43%	4.31%	-2.15%	-0.55%	-0.01%	1.56%
Dividend per Share ²	-	-	-	-	-	-	-	0.0285
Rate of return	-	-	-	-	-	-	-	0.03%
EPS ²	-1.65	-1.32	-1.42	2.42	-0.6	-0.2926	0.8116	2.137
Distribution rate	-	-	-	-	-	-	-	1.33%
Net sales ¹	-	225.6	837.7	4,526	2,124	3,295	5,255	7,951
EBITDA ¹	-1,290	-1,302	-1,225	2,191	-364.3	78.3	1,235	2,785
EBIT ¹	-1,313	-1,351	-1,331	2,049	-558.2	-258.4	813.6	2,326
Net income ¹	-1,177	-1,075	-1,168	2,028	-514.5	-258.4	753.6	2,009
Net Debt ¹	-2,492	-1,792	-225.1	1,425	1,026	-3,302	-4,785	-7,325
Reference price ²	32.00	27.70	38.04	42.12	57.04	89.60	89.60	89.60
Nbr of stocks (in thousands)	7,87,057	8,17,057	8,41,057	8,41,057	8,97,575	9,21,143	9,21,143	-
Announcement Date	31/03/21	30/03/22	15/03/23	18/03/24	30/03/25	-	-	-

¹CNY in Million²CNY

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
AKESO, INC.	-306.26x	24.05x	1011.94x	-.--%	1.19TCr
ARGENX SE	46.3x	11.02x	39.36x	0.02%	5.03TCr
WUXI APPTEC CO., LTD.	16.91x	6.04x	13.29x	1.77%	4.21TCr
INSMED INCORPORATED	-25.72x	51.77x	-29.4x	-.--%	3.2TCr
BIONTECH SE	-26.38x	4.43x	-12.22x	-.--%	2.68TCr
WUXI BIOLOGICS (CAYMAN) INC.	30.86x	6.1x	16.89x	-.--%	1.99TCr
GENMAB A/S	16.61x	3.9x	10.31x	-.--%	1.91TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-175.88x	43.39x	-175.79x	-.--%	1.26TCr
EXELIXIS, INC.	16.6x	4.78x	11.62x	-.--%	1.18TCr
Average	-45.22x	17.28x	98.44x	0.2%	2.52TCr
Weighted average by Cap.	-14.23x	16.20x	51.92x	0.33%